Physician profile
Brian S Lim
NPI 1063455210
$4,049.75
in general payments reported to CMS, 2019-2025
25 companies · $1,034 in 2025
The $1,034 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $123 · 2023: $1,849 · 2024: $1,045 · 2025: $1,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,076 · Travel and Lodging: $836 · Education: $14.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,076.12 |
| Travel and Lodging | $836.22 |
| Education | $14.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apollo Endosurgery US INC | $1,016.14 | 2023 | Overstitch Endoscopic Suturing System |
| Takeda Pharmaceuticals U.S.A., INC. | $393.15 | 2022-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $355.36 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Regeneron Pharmaceuticals, INC. | $317.45 | 2023-2025 | Dupixent |
| Boston Scientific Corporation | $283.50 | 2023-2025 | Overstitch Endoscopic Suturing System, Overstitch Nxt Endoscopic Suturing System |
| Genzyme Corporation | $210.26 | 2024-2025 | |
| Steris Corporation | $168.94 | 2024 | |
| Phathom Pharmaceuticals, INC. | $156.75 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $153.71 | 2025 | Rezdiffra |
| Lilly USA, LLC | $142.87 | 2024-2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $126.66 | 2022-2025 | Xifaxan, Trulance |
| Medtronic, INC. | $113.30 | 2022-2023 | Bravo |
| Ardelyx, INC. | $95.95 | 2023-2025 | Ibsrela |
| Celltrion USA INC. | $94.98 | 2025 | Vegzelma |
| Abbvie INC. | $69.91 | 2023-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $64.26 | 2024 | Sucraid |
| Ironwood Pharmaceuticals, INC | $59.87 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $54.82 | 2023 | Dupixent |
| Creo Medical INC. | $33.51 | 2023 | Speedboat |
| Redhill Biopharma INC. | $31.79 | 2022-2023 | Aemcolo, Talicia, Movantik |
| Daiichi Sankyo INC. | $28.56 | 2022 | |
| Pfizer INC. | $26.09 | 2025 | |
| Evoke Pharma, INC. | $20.53 | 2023 | Gimoti |
| Celgene Corporation | $18.30 | 2023 | Zeposia |
| Endogastric Solutions, INC | $13.09 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.